Family Practice Health Centre, Women's College Research Institute, Women's College Hospital, 76 Grenville Ave Toronto, Toronto, Ontario, Canada.
Implement Sci. 2012 Jun 9;7:54. doi: 10.1186/1748-5908-7-54.
Despite evidence-based recommendations supporting long-term use of cardiac medications in patients post ST-elevation myocardial infarction, adherence is known to decline over time. Discontinuation of cardiac medications in such patients is associated with increased mortality.
METHODS/DESIGN: This is a pragmatic, cluster-randomized controlled trial with blinded outcome assessment and embedded qualitative process evaluation. Patients from one health region in Ontario, Canada who undergo a coronary angiogram during their admission for ST-elevation myocardial infarction and who survive their initial hospitalization will be included. Allocation of eligible patients to intervention or usual care will take place within one week after the angiogram using a computer-generated random sequence. To avoid treatment contamination, patients treated by the same family physician will be allocated to the same study arm. The intervention consists of recurrent, personalized, paper-based educational messages and reminders sent via post on behalf of the interventional cardiologist to the patient, family physician, and pharmacist urging long-term adherence to secondary prevention medications. The primary outcome is the proportion of patients who report in a phone interview taking all relevant classes of cardiac medications at twelve months. Secondary outcomes to be measured at three and twelve months include proportions of patients who report: actively taking each cardiac medication class of interest (item-by-item); stopping medications due to side effects; taking one or two or three medication classes concurrently; a perfect Morisky Medication Adherence Score for cardiac medication compliance; and having a discussion with their family physician about long-term adherence to cardiac medications. Self-reported measures of adherence will be validated using administrative data for prescriptions filled.
This intervention is designed to be easily generalizable. If effective, it could be implemented broadly. If it does not change medication utilization, the process evaluation will offer insights regarding how such an intervention could be optimized in future.
Clinicaltrials.gov NCT01325116.
尽管有循证医学建议支持 ST 段抬高型心肌梗死患者长期使用心脏药物,但随着时间的推移,患者的依从性会下降。此类患者停止使用心脏药物会增加死亡率。
方法/设计:这是一项实用的、基于群组的随机对照试验,采用盲法结局评估和嵌入式定性过程评估。加拿大安大略省一个卫生区域内接受 ST 段抬高型心肌梗死住院治疗并在首次住院期间接受冠状动脉造影的患者将被纳入研究。在进行冠状动脉造影后一周内,通过计算机生成的随机序列将符合条件的患者分配到干预组或常规护理组。为避免治疗污染,由同一位家庭医生治疗的患者将被分配到同一研究组。干预措施包括定期、个性化的纸质教育信息和提醒,由介入心脏病专家代表患者、家庭医生和药剂师通过邮寄发送,以敦促患者长期服用二级预防药物。主要结局是通过电话访谈报告在 12 个月时服用所有相关类别的心脏药物的患者比例。将在 3 个月和 12 个月时测量的次要结局包括:报告积极服用每个感兴趣的心脏药物类别的患者比例(逐项);因副作用停止药物治疗的患者比例;同时服用一种或两种或三种药物类别的患者比例;心脏药物依从性的完美 Morisky 药物依从性评分;以及与家庭医生讨论长期服用心脏药物的患者比例。将使用处方记录的行政数据验证患者报告的依从性测量结果。
该干预措施旨在易于推广。如果有效,它可以广泛实施。如果它没有改变药物的使用情况,那么过程评估将提供有关如何在未来优化此类干预措施的见解。
Clinicaltrials.gov NCT01325116。